J&J: Covid vaccine effective in 'mix & match' study

(CercleFinance.com) - J&J yesterday released preliminary results of an independent study showing that a booster dose of J&J's Covid serum six months after a two-dose primary vaccination with Pfizer/BioNTech's vaccine resulted in a substantial increase in antibodies and T cells.


This study thus argues in favour of "mix-and-match", i.e. the mixing of different vaccines developed by different laboratories to achieve effective immunity.

These results provide valuable scientific information for our vaccine as a mixed booster dose, J&J says. The data adds to the existing knowledge of the vaccine and the potential for the vaccine to be used in a variety of ways.

Johnson & Johnson's Covid vaccine successfully enhances humoral and cellular responses against the original SARS-CoV-2 strain, as well as the Beta and Delta variants, it added.



Copyright (c) 2021 CercleFinance.com. All rights reserved.